A therapy that retrains the body’s immune system to fight cancer has provoked excitement after more than 90% of terminally ill patients reportedly went into remission.
White blood cells were taken from patients with leukaemia, modified in the lab and then put back.
But the data has not been published or reviewed and two patients are said to have died from an extreme immune response.
Experts said the trial was exciting, but still only “a baby step.”
The news bubbled out of the American Association for the Advancement of Science’s annual meeting in Washington DC.
The lead scientist, Prof Stanley Riddell from the Fred Hutchinson Cancer Research Centre in Seattle, said all other treatments had failed in these patients and they had only two-to-five months to live.
He told the conference that: “The early data is unprecedented.”
In the trial, cells from the immune system called killer t-cells were taken out of dozens of patients. The cells normally act like bombs destroying infected tissue.
The researchers genetically modified the t-cells to engineer a new targeting mechanism – with the technical name of chimeric antigen receptors – to target acute lymphoblastic leukaemia.
Prof Riddell told the BBC: “Essentially what this process does is, it genetically reprograms the T-cell to seek out and recognise and destroy the patient’s tumour cells.
“[The patients] were really at the end of the line in terms of treatment options and yet a single dose of this therapy put more than ninety percent of these patients in complete remission where we can’t detect any of these leukaemia cells.”
But one cancer expert told me they still felt in the dark on the full significance of the study, as the data is not available.
Learn more: Excitement at new cancer treatment
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Men with prostate cancer can live longer on immunotherapy, study findson November 30, 2019 at 4:07 pm
Washington D.C. [USA], Nov 30 (ANI): In what could be a piece of great news for men with advanced prostate cancer, a new study has claimed that they can live two more years or even more on ...
- AstraZeneca's Imfinzi gets speedy FDA review for small cell lung canceron November 29, 2019 at 12:47 am
British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly ...
- Prostate cancer can rely on immunotherapy for treatment: Studyon November 28, 2019 at 4:06 pm
Washington D.C. [India], Nov 28 (ANI): The men who have tried all other ways to treat prostate cancer could now count on immunotherapy, claims a recent study. Researchers have found that a small ...
- A Small Number Of Men With Prostate Cancer Are ‘Super Responders’ To Immunotherapyon November 28, 2019 at 4:03 pm
Results from a new clinical trial have shown that some men with advanced prostate cancer can live for at least two more years on immunotherapy after exhausting all other treatment options. The work ...
- Prostate cancer: How new immunotherapy can help men with ‘very poor’ prognosison November 28, 2019 at 7:05 am
The disease is also the third most common cause of cancer deaths in the UK and has just a 30 percent survival rate for men with the late-stage form. A new immunotherapy drug for prostate cancer has ...
- Immunotherapy gives hope for 'incurable' prostate canceron November 28, 2019 at 6:38 am
“We don’t see much activity from the immune system in prostate tumours, so many oncologists thought immunotherapy wouldn’t work for this cancer type,” study author Professor Johann de Bono, from The ...
- Prostate cancer 'super responders' live for two years on immunotherapyon November 27, 2019 at 1:01 pm
Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown. Researchers found that a ...
- Engineering dendritic cell vaccines to improve cancer immunotherapyon November 27, 2019 at 2:23 am
At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we ...
- Lung cancer: AI shows who will benefit from immunotherapyon November 25, 2019 at 7:30 am
As it is difficult for doctors to detect it early on, people with lung cancer need to receive the best, most targeted therapy in order to make a positive outlook more likely. Immunotherapy is an ...
- Investing In The Holy Grail Of Cancer Treatment: Immunotherapyon November 22, 2019 at 10:36 am
Cancer is the second leading cause of death globally, and conventional treatment methods such as surgery, chemotherapy and radiotherapy have limited efficacy. Immunotherapy has emerged as the next ...
via Bing News